Home » INTERMUNE THIRD-QUARTER NET LOSS WIDENS
INTERMUNE THIRD-QUARTER NET LOSS WIDENS
Biotechnology company InterMune Inc. (ITMN.O: Quote, Profile, Research) on Thursday said its third-quarter net loss widened due to an inventory charge and higher expenses. The Brisbane, California-based company reported a net loss of $23.8 million, or 74 cents per share, compared with a loss of $12.9 million, or 40 cents a share, a year earlier.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May